ArticleEuro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin2017
Control measures following a case of imported Lassa fever from Togo, North Rhine Westphalia, Germany, 2016.
Article in Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 1 synthesis or guideline pooled it, 47 citations in OpenAlex.
- Clinical characterization of Lassa fever: A systematic review of clinical reports and research to inform clinical trial design.PLoS neglected tropical diseases · 2021Pooled it
- Autopsy practices for high-consequence infectious diseases: global guidelines, alternatives, and the BSL-4 gap.Emerging microbes & infections · 2026Review
- Beyond pathogen-specific preparedness: adaptable laboratory systems for emerging infections.The Lancet regional health. Europe · 2026Article
- Mapping the scientific landscape of Lassa virus: a 55-year bibliometric study (1970-2025).Science in One Health · 2026Article
- Lassa fever in African green monkeys: Clinical disease and fatal outcome are associated with systemic viral dissemination and inflammation.Cell reports. Medicine · 2025Article
- Is there sufficient evidence to inform personal protective equipment choices for healthcare workers caring for patients with viral hemorrhagic fevers?Canada communicable disease report = Releve des maladies transmissibles au Canada · 2025Article
- Lassa fever in Nigeria: epidemiology and risk perception.Scientific reports · 2024Article
- Knowledge and practices associated with Lassa fever in rural Nigeria: Implications for prevention and control.Journal of public health in Africa · 2023Article
- Understanding the transmission pathways of Lassa fever: A mathematical modeling approach.Infectious Disease Modelling · 2023Article
- Preparing for patients with high-consequence infectious diseases: Example of a high-level isolation unit.PloS one · 2022Article
- Epidemiological trends of Lassa fever in Nigeria, 2018-2021.PloS one · 2022Article
- A mixed-methods analysis of personal protective equipment used in Lassa fever treatment centres in Nigeria.Infection prevention in practice · 2021Article
- An exploration of the protective effect of rodent species richness on the geographical expansion of Lassa fever in West Africa.PLoS neglected tropical diseases · 2021Article
- U.S. Medical Examiner/Coroner capability to handle highly infectious decedents.Forensic science, medicine, and pathology · 2019Article
- Diagnostics for Lassa fever virus: a genetically diverse pathogen found in low-resource settings.BMJ global health · 2019Article
- Hemorrhagic Fever-Causing Arenaviruses: Lethal Pathogens and Potent Immune Suppressors.Frontiers in immunology · 2019Review
- Caseload and Case Fatality of Lassa Fever in Nigeria, 2001-2018: A Specialist Center's Experience and Its Implications.Frontiers in public health · 2019Article
- Absence of Nosocomial Transmission of Imported Lassa Fever during Use of Standard Barrier Nursing Methods.Emerging infectious diseases · 2018Article
- New Lineage of Lassa Virus, Togo, 2016.Emerging infectious diseases · 2018Article
- Lessons learnt from imported cases and onward transmission of Lassa fever in Europe support broader management of viral haemorrhagic fevers.Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin · 2017Article
Corrections and comments
- Commented on by
Authors and funding
35 authors at 8 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
In a patient transferred from Togo to Cologne, Germany, Lassa fever was diagnosed 12 days post mortem. Sixty-two contacts in Cologne were categorised according to the level of exposure, and gradual infection control measures were applied. No clinical signs of Lassa virus infection or Lassa specific antibodies were observed in the 62 contacts. Thirty-three individuals had direct contact to blood, other body fluids or tissue of the patients. Notably, with standard precautions, no transmission occurred between the index patient and healthcare workers. However, one secondary infection occurred in an undertaker exposed to the corpse in Rhineland-Palatinate, who was treated on the isolation unit at the University Hospital of Frankfurt. After German authorities raised an alert regarding the imported Lassa fever case, an American healthcare worker who had cared for the index patient in Togo, and who presented with diarrhoea, vomiting and fever, was placed in isolation and medevacked to the United States. The event and the transmission of Lassa virus infection outside of Africa underlines the need for early diagnosis and use of adequate personal protection equipment (PPE), when highly contagious infections cannot be excluded. It also demonstrates that larger outbreaks can be prevented by infection control measures, including standard PPE.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.